Sudeh Izadmehr
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sudeh Izadmehr has a total of 149 co-authors. Here are the top co-authors by number of shared publications:
- Matthew D. Galsky
Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
99 shared publications - Sacha Gnjatic
Icahn School of Medicine at Mount Sinai, New York, New York, United States
99 shared publications - Adam M. Farkas
Icahn School of Medicine at Mount Sinai 1 Division of Hematology and Medical Oncology, Tisch Cancer Institute New York, New York
73 shared publications Amir Horowitz
Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA
53 shared publicationsLi Wang
Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, USA
53 shared publications- Austin Hake
Affiliation Department of Family, Center for Medical Humanities, Compassionate Care & Bioethics, Population & Preventative Medicine, Renaissance School of Medicine at Stony Brook University, Stony Brook, New York, United States of America
51 shared publications
Latest Publications
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Gemcitabine plus Nivolumab with Carboplatin or Oxaliplatin in Cisplatin-Ineligible Patients with Metastatic Urothelial Carcinoma: A Randomized Phase II Trial
Figure S1 shows the CONSORT diagram.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Gemcitabine plus Nivolumab with Carboplatin or Oxaliplatin in Cisplatin-Ineligible Patients with Metastatic Urothelial Carcinoma: A Randomized Phase II Trial
Figure S1 shows the CONSORT diagram.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Data from Gemcitabine plus Nivolumab with Carboplatin or Oxaliplatin in Cisplatin-Ineligible Patients with Metastatic Urothelial Carcinoma: A Randomized Phase II Trial
Purpose:Oxaliplatin has demonstrated the ability to sensitize tumors to immune checkpoint blockade through its immunomodulatory properties in model systems of cancer. This randomized trial aimed to evaluate gemcitabine/oxaliplatin and gemcitabine/carboplatin, each combined with nivolumab, in cisplatin-ineligible patients with metastatic urothelial carcinoma (mUC).Patients and Methods:Cisplatin-ineligible patients with mUC were randomized 1:1 to gemcitabine/carboplatin plus nivolumab or gemcitabine/oxaliplatin plus nivolumab for up to 6 cycles, followed by nivolumab monotherapy. A pick-the-winner design was employed with objective response rate (ORR) as the primary endpoint. Secondary endpoints included progression-free survival and overall survival (OS). Exploratory analyses evaluated plasma protein analytes, circulating immune cell populations, and circulating tumor cells.Results:Forty-nine patients were enrolled (carboplatin arm, N = 25; oxaliplatin arm, N = 24). The ORRs were 69.6% [95% confidence interval (CI), 0.48–0.87] for the carboplatin arm and 33.3% (95% CI, 0.15–0.57) for the oxaliplatin arm. The median OS rates were 24.74 and 16.43 months for the carboplatin and oxaliplatin arms, respectively (hazard ratio, 1.99; 95% CI, 0.94–4.22; P = 0.07). Exploratory biomarker analyses revealed sustained adaptive immune activation in the carboplatin arm and features suggestive of tumor-promoting inflammation in the oxaliplatin arm.Conclusions:Oxaliplatin-based chemoimmunotherapy, versus carboplatin-based chemoimmunotherapy, did not yield a higher response rate, challenging assumptions based on preclinical data.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Gemcitabine plus Nivolumab with Carboplatin or Oxaliplatin in Cisplatin-Ineligible Patients with Metastatic Urothelial Carcinoma: A Randomized Phase II Trial
Purpose:Oxaliplatin has demonstrated the ability to sensitize tumors to immune checkpoint blockade through its immunomodulatory properties in model systems of cancer. This randomized trial aimed to evaluate gemcitabine/oxaliplatin and gemcitabine/carboplatin, each combined with nivolumab, in cisplatin-ineligible patients with metastatic urothelial carcinoma (mUC).Patients and Methods:Cisplatin-ineligible patients with mUC were randomized 1:1 to gemcitabine/carboplatin plus nivolumab or gemcitabine/oxaliplatin plus nivolumab for up to 6 cycles, followed by nivolumab monotherapy. A pick-the-winner design was employed with objective response rate (ORR) as the primary endpoint. Secondary endpoints included progression-free survival and overall survival (OS). Exploratory analyses evaluated plasma protein analytes, circulating immune cell populations, and circulating tumor cells.Results:Forty-nine patients were enrolled (carboplatin arm, N = 25; oxaliplatin arm, N = 24). The ORRs were 69.6% [95% confidence interval (CI), 0.48–0.87] for the carboplatin arm and 33.3% (95% CI, 0.15–0.57) for the oxaliplatin arm. The median OS rates were 24.74 and 16.43 months for the carboplatin and oxaliplatin arms, respectively (hazard ratio, 1.99; 95% CI, 0.94–4.22; P = 0.07). Exploratory biomarker analyses revealed sustained adaptive immune activation in the carboplatin arm and features suggestive of tumor-promoting inflammation in the oxaliplatin arm.Conclusions:Oxaliplatin-based chemoimmunotherapy, versus carboplatin-based chemoimmunotherapy, did not yield a higher response rate, challenging assumptions based on preclinical data.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Gemcitabine plus Nivolumab with Carboplatin or Oxaliplatin in Cisplatin-Ineligible Patients with Metastatic Urothelial Carcinoma: A Randomized Phase II Trial
Figure S3 shows peripheral immune cell changes of the two groups.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Gemcitabine plus Nivolumab with Carboplatin or Oxaliplatin in Cisplatin-Ineligible Patients with Metastatic Urothelial Carcinoma: A Randomized Phase II Trial
Figure S3 shows peripheral immune cell changes of the two groups.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Gemcitabine plus Nivolumab with Carboplatin or Oxaliplatin in Cisplatin-Ineligible Patients with Metastatic Urothelial Carcinoma: A Randomized Phase II Trial
Table S2 shows CyTOF panel and cell cluster definitions.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Gemcitabine plus Nivolumab with Carboplatin or Oxaliplatin in Cisplatin-Ineligible Patients with Metastatic Urothelial Carcinoma: A Randomized Phase II Trial
Table S2 shows CyTOF panel and cell cluster definitions.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Gemcitabine plus Nivolumab with Carboplatin or Oxaliplatin in Cisplatin-Ineligible Patients with Metastatic Urothelial Carcinoma: A Randomized Phase II Trial
Table S4 shows representativeness of study participants.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Gemcitabine plus Nivolumab with Carboplatin or Oxaliplatin in Cisplatin-Ineligible Patients with Metastatic Urothelial Carcinoma: A Randomized Phase II Trial
Table S4 shows representativeness of study participants.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Gemcitabine plus Nivolumab with Carboplatin or Oxaliplatin in Cisplatin-Ineligible Patients with Metastatic Urothelial Carcinoma: A Randomized Phase II Trial
Table S1 shows the Olink IO panel analytes.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Gemcitabine plus Nivolumab with Carboplatin or Oxaliplatin in Cisplatin-Ineligible Patients with Metastatic Urothelial Carcinoma: A Randomized Phase II Trial
Table S1 shows the Olink IO panel analytes.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Gemcitabine plus Nivolumab with Carboplatin or Oxaliplatin in Cisplatin-Ineligible Patients with Metastatic Urothelial Carcinoma: A Randomized Phase II Trial
Figure S4 shows correlation between Olink and overall survival.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Gemcitabine plus Nivolumab with Carboplatin or Oxaliplatin in Cisplatin-Ineligible Patients with Metastatic Urothelial Carcinoma: A Randomized Phase II Trial
Figure S4 shows correlation between Olink and overall survival.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Gemcitabine plus Nivolumab with Carboplatin or Oxaliplatin in Cisplatin-Ineligible Patients with Metastatic Urothelial Carcinoma: A Randomized Phase II Trial
Figure S6 shows correlation between CTC and overall survival.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Gemcitabine plus Nivolumab with Carboplatin or Oxaliplatin in Cisplatin-Ineligible Patients with Metastatic Urothelial Carcinoma: A Randomized Phase II Trial
Figure S6 shows correlation between CTC and overall survival.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Gemcitabine plus Nivolumab with Carboplatin or Oxaliplatin in Cisplatin-Ineligible Patients with Metastatic Urothelial Carcinoma: A Randomized Phase II Trial
Table S3 shows detailed power calculation.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Gemcitabine plus Nivolumab with Carboplatin or Oxaliplatin in Cisplatin-Ineligible Patients with Metastatic Urothelial Carcinoma: A Randomized Phase II Trial
Table S3 shows detailed power calculation.